Carbamazepine extended-release capsules: a new treatment option for bipolar I disorder.

Published

Journal Article (Review)

Carbamazepine has a long history in psychiatry and neurology. More recently, carbamazepine extended-release capsules have been approved by the US Food and Drug Administration for the treatment of manic and mixed episodes associated with bipolar I disorder. This decision represents a significant step forward for the agent, which was first described to have efficacy in the disorder in the early 1970s. Approval of carbamazepine extended-release capsules was aided by two large placebo-controlled, 3-week trials. Using nearly identical protocols, these trials demonstrated that monotherapy with carbamazepine extended-release capsules was effective for the treatment of acute mania in patients with bipolar I disorder. Recent data collected based on this new formulation of carbamazepine illustrate the need for education about the utility of this compound in bipolar disorder.

Full Text

Duke Authors

Cited Authors

  • Weisler, RH

Published Date

  • September 2005

Published In

Volume / Issue

  • 5 / 5

Start / End Page

  • 587 - 595

PubMed ID

  • 16162082

Pubmed Central ID

  • 16162082

Electronic International Standard Serial Number (EISSN)

  • 1744-8360

Digital Object Identifier (DOI)

  • 10.1586/14737175.5.5.587

Language

  • eng

Conference Location

  • England